Hydroxyurea can be used to increase mouse c-kit+Thy-1. 1(lo)Lin-/loSca-1(+) hematopoietic cell number and frequency in cell cycle in vivo

Blood. 1997 Dec 1;90(11):4354-62.

Abstract

The DNA synthesis inhibitor hydroxyurea (HU) was administered to determine whether it induces changes in the cell-cycle status of primitive hematopoietic stem cells (HSCs)/progenitors. Administration of HU to mice leads to bone marrow accumulation of c-kit+Thy-1.1(lo)Lin-/loSca-1(+) (KTLS) cells in S/G2/M phases of the cell cycle. HU is a relatively nontoxic, reversible cell-cycle agent that can lead to approximately a threefold expansion of KTLS cells in vivo and approximately an eightfold increase in the number of KTLS cells in S/G2/M. HSCs in HU-treated mice have undiminished multilineage long-term and short-term clonal reconstitution activity.

MeSH terms

  • Animals
  • Calcium Channel Blockers / pharmacology
  • Cell Count
  • Cell Cycle
  • Cell Separation
  • Cells, Cultured
  • Flow Cytometry
  • Hematopoietic Stem Cell Transplantation
  • Hematopoietic Stem Cells / cytology*
  • Hematopoietic Stem Cells / drug effects
  • Hydroxyurea / pharmacology*
  • Mice
  • Nucleic Acid Synthesis Inhibitors / pharmacology*
  • Thy-1 Antigens / analysis*
  • Verapamil / pharmacology

Substances

  • Calcium Channel Blockers
  • Nucleic Acid Synthesis Inhibitors
  • Thy-1 Antigens
  • Verapamil
  • Hydroxyurea